Salud financiera de hoja de balance de NextCell Pharma

Salud financiera controles de criterios 4/6

NextCell Pharma tiene un patrimonio de los accionistas total de SEK65.9M y una deuda total de SEK0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son SEK81.2M y SEK15.3M respectivamente.

Información clave

Ratio deuda-patrimonio

kr0

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	kr30.39m
Patrimonio	kr55.84m
Total pasivo	kr14.70m
Activos totales	kr70.54m

Actualizaciones recientes sobre salud financiera

Here's Why We're Not Too Worried About NextCell Pharma's (STO:NXTCL) Cash Burn Situation

May 31

Recent updates

We Think NextCell Pharma (STO:NXTCL) Needs To Drive Business Growth Carefully

Mar 09

We're Not Very Worried About NextCell Pharma's (STO:NXTCL) Cash Burn Rate

Oct 07

NextCell Pharma (STO:NXTCL) Is In A Good Position To Deliver On Growth Plans

May 23

NextCell Pharma (STO:NXTCL) Is In A Good Position To Deliver On Growth Plans

Feb 01

We Think NextCell Pharma (STO:NXTCL) Can Afford To Drive Business Growth

Sep 21

Here's Why We're Not Too Worried About NextCell Pharma's (STO:NXTCL) Cash Burn Situation

May 31

We Think NextCell Pharma (STO:NXTCL) Needs To Drive Business Growth Carefully

Feb 15

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo (SEK59.7M) de NXTCL superan a sus pasivos a corto plazo (SEK11.9M).

Pasivo a largo plazo: Los activos a corto plazo de NXTCL (SEK59.7M) superan a sus pasivos a largo plazo (SEK3.4M).

Historial y análisis de deuda-patrimonio

Nivel de deuda: NXTCL está libre de deudas.

Reducción de la deuda: NXTCL no ha tenido ninguna deuda en los últimos 5 años.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: NXTCL tiene menos de un año de cash runway basado en su flujo de caja libre actual.

Pronóstico de cash runway: NXTCL tiene menos de un año de cash runway si el flujo de caja libre sigue reduciéndose a tasas históricas de 22.3% cada año

Salud financiera de hoja de balance de NextCell Pharma

Salud financiera controles de criterios 4/6

Información clave

Actualizaciones recientes sobre salud financiera

We Think NextCell Pharma (STO:NXTCL) Needs To Drive Business Growth Carefully

We're Not Very Worried About NextCell Pharma's (STO:NXTCL) Cash Burn Rate

NextCell Pharma (STO:NXTCL) Is In A Good Position To Deliver On Growth Plans

NextCell Pharma (STO:NXTCL) Is In A Good Position To Deliver On Growth Plans

We Think NextCell Pharma (STO:NXTCL) Can Afford To Drive Business Growth

Here's Why We're Not Too Worried About NextCell Pharma's (STO:NXTCL) Cash Burn Situation

Recent updates

Nextcell Pharma AB Elects Hans-Peter Ekre as New Chairman of the Board

Second quarter 2024 earnings released

NextCell Pharma AB Announces Swedish Health and Social Care Inspectorate Grants Their Cellaviva Tissue Establishment Permission to Handle Amniotic Tissue

NextCell Pharma AB, Annual General Meeting, Nov 28, 2024

Anders Essen-Möller Resigns as Chairman of NextCell Pharma AB

The Swedish Medical Products Agency Approves Subgroup Analysis in NextCell Pharma AB's ProTrans-Young study

New minor risk - Share price stability

First quarter 2024 earnings released

Nextcell Pharma Announces Updates Regarding Nextcell's Clinical Trials with Protrans

Full year 2023 earnings released

NextCell Pharma AB to Report Fiscal Year 2024 Results on Oct 24, 2024

Third quarter 2023 earnings released

NextCell Pharma AB Announces Treatment Start of Severe Pneumonia with High Dose of ProTrans

New minor risk - Share price stability

Second quarter 2023 earnings released

We Think NextCell Pharma (STO:NXTCL) Needs To Drive Business Growth Carefully

First quarter 2023 earnings released

NextCell Pharma AB to Report Fiscal Year 2023 Final Results on Nov 09, 2023

NextCell Pharma AB Announces First Pediatric Patients Treated with ProTrans in Type-1 Diabetes Phase II Study

Less than half of directors are independent

Full year 2022 earnings released

Nextcell Pharma AB Announces Trial with Protrans Gets Green Light for Phase Ii Part

Nextcell Cell Therapy Shows Long-Term Effect in Two Independent Diabetes Studies "ProTrans-Repeat" and "ProTrans-Obs"- Live Presentation

Nextcell Pharma AB Announces Protrans Cell Therapy Provides Long-Term Effect in Type-1 Diabetes with A Single Treatment

NextCell Pharma AB Announces Type-1 Diabetes Patients Receiving Two Treatments with A High Dose of Protrans Cell Therapy

We're Not Very Worried About NextCell Pharma's (STO:NXTCL) Cash Burn Rate

NextCell Pharma AB Announces ProTrans Cell Therapy to Be Granted Patent Protection Beyond Europe

Third quarter 2022 earnings released

NextCell Pharma AB Announces Patients in the First Part of Pediatric Diabetes Trial with Nextcell's Protrans Treated

The European Patent Office intends to grant a Patent to NextCell Pharma AB for Selection Algorithm

NextCell Pharma (STO:NXTCL) Is In A Good Position To Deliver On Growth Plans

Second quarter 2022 earnings released

Less than half of directors are independent

NextCell Pharma AB Announces First Age Group Treated in Paediatric Diabetes Study with Protrans

NextCell Pharma AB Announces Clinical Trial ProTrans19+CA Expanded to Include an Additional Site: The Jewish General Hospital In Montreal, Canada

NextCell Pharma AB Announces Pediatric Diabetes Study with ProTrans in Progress

NextCell Pharma (STO:NXTCL) Is In A Good Position To Deliver On Growth Plans

First quarter 2022 earnings: Revenues in line with analyst expectations

NextCell Pharma AB to Report Fiscal Year 2022 Final Results on Nov 03, 2022

Director recently bought kr61k worth of stock

We Think NextCell Pharma (STO:NXTCL) Can Afford To Drive Business Growth

Third quarter 2021 earnings released

NextCell Pharma AB Announces COVID-19 Patient Treated with ProTrans

Here's Why We're Not Too Worried About NextCell Pharma's (STO:NXTCL) Cash Burn Situation

NextCell Presents Their Latest Phase II Clinical Data at ISCT 2021

NextCell Pharma AB Announces That Both the Canadian and Swedish Covid-19 Studies Have Been Initiated and Are Now Ready to Include Patients with Severe Pneumonia Triggered by Sars-Cov-2 Infection

Nextcelpharmama AB Recruitments Start for the Protrans Study for Treatment of Covid-19

Second quarter 2021 earnings released

New 90-day low: kr15.30

We Think NextCell Pharma (STO:NXTCL) Needs To Drive Business Growth Carefully

NextCell Pharma AB Announces Canadian Trial for ProTrans in COVID-19

First quarter 2021 earnings released: kr0.23 loss per share (vs kr0.20 loss in 1Q 2020)

New 90-day low: kr16.15

NextCell Pharma AB, Annual General Meeting, Nov 24, 2021

New 90-day low: kr16.80

Nextcell Pharma AB Announces Observational Study, Protrans-Obs, receives Approval by the Swedish Ethical Review Board

New 90-day low: kr18.30

NextCell Pharma AB Supports ProTrans Study for Children and Adolescents

Nextcell Starts Eurostars Funded Project Bioscale

Full year earnings released - kr0.92 loss per share

New 90-day high: kr23.80

New 90-day high - kr19.40

NextCell Pharma AB to Report Fiscal Year 2020 Final Results on Nov 12, 2020

New 90-day high - kr13.30

NextCell Pharma AB has completed a Follow-on Equity Offering in the amount of SEK 25.100028 million.

Análisis de la situación financiera

Historial y análisis de deuda-patrimonio

Hoja de balance

Análisis de cash runway